Pearson James A, McKinney Eoin F, Walker Lucy S K
Diabetes Research Group, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, Wales, UK.
Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, Cambridge, England, UK.
Immunother Adv. 2021 Nov 24;1(1):ltab024. doi: 10.1093/immadv/ltab024. eCollection 2021 Jan.
Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell-mediated destruction of the insulin-producing β cells in the pancreas. Similar to other autoimmune diseases, the incidence of T1D is increasing globally. The discovery of insulin 100 years ago dramatically changed the outlook for people with T1D, preventing this from being a fatal condition. As we celebrate the centenary of this milestone, therapeutic options for T1D are once more at a turning point. Years of effort directed at developing immunotherapies are finally starting to pay off, with signs of progress in new onset and even preventative settings. Here, we review a selection of immunotherapies that have shown promise in preserving β cell function and highlight future considerations for immunotherapy in the T1D setting.
1型糖尿病（T1D）是一种自身免疫性疾病，其特征是T细胞介导的胰腺中产生胰岛素的β细胞被破坏。与其他自身免疫性疾病一样，T1D在全球的发病率正在上升。100年前胰岛素的发现极大地改变了T1D患者的前景，使其不再是一种致命疾病。在我们庆祝这一里程碑百年之际，T1D的治疗选择再次处于转折点。多年来致力于开发免疫疗法的努力终于开始取得成效，在新发疾病甚至预防方面都有进展迹象。在此，我们回顾了一系列在保留β细胞功能方面显示出前景的免疫疗法，并强调了T1D背景下免疫疗法未来的考虑因素。
